Anti-brdu antibodies and methods of use

Abstract

The invention provides anti-BRDU antibodies and methods of using the same.

1 . (canceled) 
     
     
         2 . (canceled) 
     
     
         3 . (canceled) 
     
     
         4 . (canceled) 
     
     
         5 . A humanized anti-BRDU antibody, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 01, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 13, and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 05, (d) HVR-L1 comprising the amino acid sequence of SEO ID NO: 06, (e) HVR-L2 comprising the amino acid sequence of SEO ID NO: 07, and (f) HVR-L3 comprising the amino acid sequence of SEO ID NO: 08, wherein each HVR contains no more than one amino acid substitution. 
     
     
         6 . (canceled) 
     
     
         7 . (canceled) 
     
     
         8 . (canceled) 
     
     
         9 . (canceled) 
     
     
         10 . (canceled) 
     
     
         11 . (canceled) 
     
     
         12 . (canceled) 
     
     
         13 . (canceled) 
     
     
         14 . (canceled) 
     
     
         15 . (canceled) 
     
     
         16 . (canceled) 
     
     
         17 . (canceled) 
     
     
         18 . (canceled) 
     
     
         19 . (canceled) 
     
     
         20 . A covalent complex comprising the humanized anti-BRDU antibody according to  claim 5  and a BRDU conjugated to a cysteine residue. 
     
     
         21 . (canceled) 
     
     
         22 . (canceled) 
     
     
         23 . (canceled) 
     
     
         24 . (canceled) 
     
     
         25 . (canceled) 
     
     
         26 . (canceled) 
     
     
         27 . (canceled) 
     
     
         28 . (canceled) 
     
     
         29 . (canceled) 
     
     
         30 . (canceled) 
     
     
         31 . (canceled) 
     
     
         32 . (canceled) 
     
     
         33 . (canceled) 
     
     
         34 . (canceled) 
     
     
         35 . The humanized anti-BRDU antibody according to  claim 5 , wherein the antibody comprises a VH with the amino acid sequence of SEQ ID NO: 09 modified at position 53 to a cysteine (according to Kabat numbering), and a VL with the amino acid sequence of SEQ ID NO: 10. 
     
     
         36 . A complex comprising the humanized anti-BRDU antibody according to  claim 5  and a nucleic acid comprising BRDU. 
     
     
         37 . A pharmaceutical formulation comprising the humanized anti-BRDU antibody according to  claim 5  and a pharmaceutically acceptable carrier. 
     
     
         38 . The anti-BRDU antibody of  claim 5 , wherein the antibody is a multispecific antibody. 
     
     
         39 . The anti-BRDU antibody of  claim 38 , wherein the antibody binds to BRDU and a cell surface molecule.